Thermo Fisher Scientific (TMO) Other financing activities (2009 - 2026)

Thermo Fisher Scientific has reported Other financing activities for 18 years, with the latest figure at -$6.0 million in Q2 2026.

• Other financing activities for Q2 2026 came in at -$6.0 million, up 85.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $120.0 million (up 126.42% YoY), and the FY2025 annual result was $90.0 million, down 53.85% from the prior year.
• Other financing activities fell to -$6.0 million in Q2 2026, from $39.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $110.0 million in Q1 2024 and troughed at -$42.0 million in Q2 2025.
• A 5-year average of $20.3 million and a median of $19.0 million in 2022 frame the typical range for Other financing activities.
• The widest annual swing landed in 2022, when Other financing activities tumbled 270.0%; it then jumped 775.0% in 2024.
• A 5-year view of Other financing activities shows it stood at $20.0 million in 2022, then fell by 30.0% to $14.0 million in 2023, then sank by 221.43% to -$17.0 million in 2024, then surged by 635.29% to $91.0 million in 2025, then plunged by 106.59% to -$6.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were -$6.0 million in Q2 2026, $39.0 million in Q1 2026, and $91.0 million in Q4 2025.